{{Rsnum
|rsid=6993813
|Chromosome=8
|position=119039999
|Orientation=plus
|GMAF=0.3788
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene=COLEC10
|Gene_s=COLEC10
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 23.9 | 54.9 | 21.2
| HCB | 31.1 | 55.6 | 13.3
| JPT | 31.0 | 51.3 | 17.7
| YRI | 69.0 | 27.5 | 3.5
| ASW | 50.9 | 38.6 | 10.5
| CHB | 31.1 | 55.6 | 13.3
| CHD | 37.1 | 55.2 | 7.6
| GIH | 54.5 | 38.6 | 6.9
| LWK | 52.8 | 42.6 | 4.6
| MEX | 29.3 | 46.6 | 24.1
| MKK | 44.8 | 40.3 | 14.9
| TSI | 42.4 | 39.4 | 18.2
| HapMapRevision=28
}}rs6993813 increases susceptibility to Bone mineral density variations, lower for carriers of the A allele {{PMID|18445777}}

rs6993813 increases susceptibility to Osteoporotic fractures for carriers of the A allele {{PMID|18445777}}

{{GWAS Summary
|SNP=rs6993813
|PubMedID=18445777
|Condition=Bone mineral density (hip)
|Gene=OPG
|Risk Allele=C
|pValue=3.00E-011
|OR=0.09
|95CI=0.07-0.12) SD decreas
}}

{{omim
|desc=BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 10; BMND10
|id=612113
|rsnum=6993813
}}

{{PharmGKB
|RSID=rs6993813
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18445777; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Multiple Genetic Loci for Bone Mineral Density and Fractures (Initial Sample Size: 5,861 individuals; Replication Sample Size: 7,925 individuals; Risk Allele: rs6993813-C). This variant is associated with Bone mineral density (hip).
|Drugs=
|Drug Classes=
|Diseases=Bone Diseases; Bone Diseases, Metabolic; Fractures, Bone
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356559
}}

{{PMID Auto
|PMID=22079369
|Title=TNFRSF11B gene haplotype and its association with bone mineral density variations in postmenopausal Mexican-Mestizo women
}}

{{PMID Auto
|PMID=22824048
|Title=Opposite associations of osteoprotegerin and ZBTB40 polymorphisms with bone mineral density of the hip in postmenopausal Taiwanese women
}}

{{PMID Auto
|PMID=19181680
|Title=Common variants in the region around Osterix are associated with bone mineral density and growth in childhood.
|OA=1
}}

{{PMID Auto
|PMID=20534768
|Title=OPG and RANK polymorphisms are both associated with cortical bone mineral density: findings from a metaanalysis of the Avon longitudinal study of parents and children and gothenburg osteoporosis and obesity determinants cohorts.
|OA=1
}}

{{PMID Auto
|PMID=20554715
|Title=Analysis of recently identified osteoporosis susceptibility genes in Han Chinese women.
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6993813
|overall_frequency_n=75
|overall_frequency_d=128
|overall_frequency=0.585938
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=68
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=24130145
|Title=Polymorphism of LRP5, but not of TNFRSF11B, is associated with a decrease in bone mineral density in postmenopausal maya-mestizo women
}}

{{PMID Auto
|PMID=23531404
|Title=Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women.
}}

{{PMID Auto
|PMID=25105978
|Title=An Osteoprotegerin Gene Polymorphism Is Associated with an Increased Risk of Hip Fracture in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Observational Cohort Study
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}